Losartan and Memory

NCT ID: NCT05828940

Last Updated: 2023-04-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 41 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-10-01
• Study Completion Date: 2022-03-31

Brief Summary

This study investigates the effect of a single dose of 50mg losartan vs placebo on BOLD signal during memory encoding.

Detailed Description

The commonly prescribed antihypertensive drug losartan targets the renin-angiotensin system - a hormone system regulating blood pressure - by acting as an angiotensin receptor antagonist. The drug prevents a docking of the protein angiotensin IV to AT1 receptors, which leads to a dilation if vessels and a reduction in blood pressure. However, the increase in free angiotensin IV has also been associated with an increase in synaptic plasticity, the cellular mechanism involved in learning and memory. As such, losartan appears to have cognition-enhancing properties, in a way that a single dose of 50mg improves prospective memory in healthy humans . However, preliminary pre-clinical results also suggest that a single injection of the drug improves fear extinction in rodents, which is the equivalent to human cognitive-behavioural therapy for anxiety disorders . Furthermore, compared to other antihypertensive drugs, regular losartan treatment appears to prevent the development of post-traumatic stress disorder following trauma exposition . Such results suggest that the renin-angiotensin system may play a key role in the prevention of anxiety.

In this study, we investigate the effect kof probing the renin-angiotensin system on memory encoding, which has previously been shown to be impaired in PTSD. In a double-blind, randomised between-groups design, 40 healthy volunteers with moderate to high levels of trait anxiety are randomised to a group receiving a single dose of losartan (50mg) versus placebo. When peak plasma levels are reached, participants work on a battery of behavioural and neural measures of emotional information processing. These tasks will include an fMRI task where participants will see images of animals and landscapes on the screen and categorise these accordingly, to be tested for memory for these images in a later task.

The results from this study will help us understand how the renin-angiotensin system affects memory formation, and they will help us establish a battery of tasks that sensitively respond to such manipulations. Such information will ultimately lead to the development of losartan and similar agents for the more effective and more compact treatment of anxiety disorders.

Conditions

PTSD

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

placebo

microcellulose

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

oral tablet, over-encapuslated

losartan

50mg losartan (Cozaar)

Group Type: EXPERIMENTAL

Losartan Potassium

Intervention Type: DRUG

oral tablet, over-encapsulated

Interventions

Losartan Potassium

oral tablet, over-encapsulated

Intervention Type: DRUG

Placebo

oral tablet, over-encapuslated

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• willing and able to provide informed consent
• male or Female, aged 18-50 years
• body mass index (BMI) of 18-30 kg/m2
• non- or light-smoker (< 5 cigarettes a day)
• STAIT score of at least 40

Exclusion Criteria

• Female participant who is pregnant or breast-feeding
• CNS-active medication during the last 6 weeks
• Current blood pressure or other heart medication (especially aliskiren or beta blockers)
• Diagnosis of intravascular fluid depletion or dehydration
• Past or present DSM-IV axis-I diagnosis or suspected diagnosis (from SCID results at screening)
• Alcohol or substance abuse
• First-degree family member with a history of a severe psychiatric disease
• Impaired liver or kidney function
• Lifetime history of epilepsy or other neurological disease, systemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
• High or moderate risk of coronavirus, based on the NHS checklist for coronavirus vulnerability https://www.nhs.uk/conditions/coronavirus-covid-19/people-at-higher-risk/whos-at-higher-risk-from-coronavirus/
• Contraindication to MRI (e.g. metal implant)
• Insufficient English skills
• participated in another study involving CNS-active medication during the last 6 weeks Participants will also not be able to take part if they are left-handed, due to the research MRI aspect of the study relying on group means.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Oxford

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Andrea Reinecke, PhD

Role: PRINCIPAL_INVESTIGATOR

Unoversity of Oxford

Locations

Department of Psychiatry, University of Oxford

Oxford, , United Kingdom

Countries

United Kingdom

Other Identifiers

R58494/RE003

Identifier Type: -

Identifier Source: org_study_id